Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies

OBJECTIVES: To evaluate the efficacy through 52 weeks of guselkumab, an interleukin 23-p19 subunit inhibitor, in subgroups of pooled psoriatic arthritis (PsA) patients from the DISCOVER-1 and DISCOVER-2 trials defined by baseline patient characteristics. METHODS: Adults with active PsA despite stand...

Descripción completa

Detalles Bibliográficos
Autores principales: Ritchlin, Christopher T, Mease, Philip J, Boehncke, Wolf-Henning, Tesser, John, Schiopu, Elena, Chakravarty, Soumya D, Kollmeier, Alexa P, Xu, Xie L, Shawi, May, Jiang, Yusang, Sheng, Shihong, Wang, Yanli, Xu, Stephen, Merola, Joseph F, McInnes, Iain B, Deodhar, Atul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Psoriatic Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8928386/
https://www.ncbi.nlm.nih.gov/pubmed/35296534
http://dx.doi.org/10.1136/rmdopen-2022-002195

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8928386/
https://www.ncbi.nlm.nih.gov/pubmed/35296534
http://dx.doi.org/10.1136/rmdopen-2022-002195

Ejemplares similares